日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

多西他赛再次治疗与卡巴他赛治疗转移性去势抵抗性前列腺癌患者的疗效比较

Barata, Pedro C; Corrigan, June K; La, Jennifer; Culnan, John M; Akama-Garren, Elliot; Dulberger, Karlynn N; Dumontier, Clark; Hansen, Jason; Bihn, John R; Bitting, Rhonda L; Brophy, Mary T; Cheng, Heather H; Cooperberg, Matthew R; Do, Nhan V; Dorff, Tanya; Fojo, Antonio Tito; Gaziano, J Michael; Goryachev, Sergey D; Halabi, Susan; Hauger, Richard L; Nanus, David M; Rebbeck, Timothy R; Pan, Chong-Xian; Schoen, Martin W; Swinnerton, Kaitlin N; Myrie, Kenute; Ramoni, Rachel B; Fillmore, Nathanael R; Paller, Channing J; Rettig, Matthew B

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia

美国食品药品监督管理局批准摘要:伊美替司他用于治疗部分低危至中危-1型骨髓增生异常综合征伴输血依赖性贫血患者

Kim, Nina; Pulte, E Dianne; Ehrlich, Lori A; Ionan, Alexei C; Haupert, Spencer; Vallejo, Jonathon; Green, Francis; Zheng, Nan; Wang, Yun; Liu, Jiang; Blanco, Javier G; Dorff, Sarah E; Booth, Brian; Choe, Moran; Gehrke, Brenda; Bhatnagar, Vishal; Theoret, Marc; Pazdur, Richard; De Claro, R Angelo; Norsworthy, Kelly J

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer

FDA批准摘要:Datopotamab Deruxtecan-dlnk用于治疗不可切除或转移性、HR阳性、HER2阴性乳腺癌患者

Royce, Melanie; Shah, Mirat; Zhang, Lijun; Cheng, Joyce; Bonner, Mary Kate; Pegues, Melissa; Miller, Claudia P; Leu, Lily; Price, Lauren S L; Qiu, Junshan; Yu, Jingyu; Truong, Tien M; Dorff, Sarah E; Yang, Yuching; Zhang, Nailing; Gutierrez-Lugo, Maria; Ricks, Tiffany K; Pierce, William F; Luo, Zhongjun; Kappel, Dana; Goldberg, Kirsten B; Shord, Stacy S; Tang, Shenghui; Bhatnagar, Vishal; Pazdur, Richard; Kluetz, Paul G; Amiri-Kordestani, Laleh

FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery

FDA批准摘要:Vorasidenib用于IDH突变型2级星形细胞瘤或少突胶质细胞瘤术后治疗

Barbato, Michael I; Barone, Amy K; Aungst, Stephanie L; Miller, Claudia P; Ananthula, Suryatheja; Bi, Youwei; Yang, Yuching; Li, Xiaoxue; Xiong, Ye; Fan, Jianghong; Dorff, Sarah E; Zhao, Hong; Zhou, Hua; Pradhan, Shan; Scepura, Barbara; Sinha, Arup K; Stephenson, Maritsa; Bhatnagar, Vishal; Saber, Haleh; Rahman, Nam Atiqur; Tang, Shenghui; Pazdur, Richard; Kluetz, Paul G; Larkins, Erin; Drezner, Nicole

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation

FDA批准摘要:Ivosidenib用于治疗伴有IDH1突变的复发/难治性骨髓增生异常综合征成人患者

Woods, Ashley C; Pulte, E Dianne; Wang, Xin; Vallejo, Jonathon; Chadda, Ritu; Zheng, Nan; Blanco, Javier G; Dorff, Sarah E; Li, Hongshan; Liu, Jiang; Okusanya, Olanrewaju O; Pazdur, Richard; Theoret, Marc R; de Claro, R Angelo; Norsworthy, Kelly J

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

转移性激素敏感性前列腺癌患者体重指数与总生存期的相关性:SWOG-1216患者个体数据分析

Swami, Umang; Jo, Yeonjung; Narang, Arshit; Plets, Melissa; Hage Chehade, Chadi; Gebrael, Georges; Gupta, Shilpa; Myint, Zin; Tangen, Catherine; Lara, Primo N Jr; Thompson, Ian M Jr; Hussain, Maha H A; Dorff, Tanya B; Lerner, Seth P; Agarwal, Neeraj

Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors

针对难治性或复发性生殖细胞肿瘤患者的高剂量化疗方案的多中心分析

Chehrazi-Raffle, A; Zugman, M; Ebrahimi, H; Shodiya, M O; Maldonado, E; Othman, T; Jaime-Casas, S; Barragan-Carrillo, R; Li, X; Pal, S K; Tripathi, A; Zhumkhawala, A; Hoeg, R; Oliai, C; Olin, R L; Dorff, T B; Mei, M

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

针对生化复发和晚期前列腺癌患者实施循证策略:2024 年美国前列腺癌大会共识建议

Bryce, Alan H; Agarwal, Neeraj; Beltran, Himisha; Hussain, Maha H; Sartor, Oliver; Shore, Neal; Antonarakis, Emmanuel S; Armstrong, Andrew J; Calais, Jeremie; Carducci, Michael A; Dorff, Tanya Barauskas; Efstathiou, Jason A; Gleave, Martin; Gomella, Leonard G; Higano, Celestia; Hope, Thomas A; Iagaru, Andrei; Morgans, Alicia K; Morris, David S; Morris, Michael J; Petrylak, Daniel P; Reiter, Robert E; Rettig, Matthew B; Ryan, Charles J; Sellinger, Scott B; Spratt, Daniel E; Srinivas, Sandy; Tagawa, Scott T; Taplin, Mary-Ellen; Yu, Evan Y; Zhang, Tian; McKay, Rana R; Koo, Phillip J; Crawford, E David

Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants

癌症临床试验参与者吸烟流行率及其与社会人口学变量的关系

Presant, Cary A; Till, Cathee; Vaidya, Riha; Ashing, Kimlin Tan; Warren, Graham W; Sun, Virginia; Salgia, Ravi; Massarelli, Erminia; Mortimer, Joanne E; Pal, Sumanta; Dorff, Tanya; Amini, Arya; Erhunmwunsee, Loretta; Phillips, Tanyanika; Hershman, Dawn L; Unger, Joseph M

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

将普遍的生殖系基因检测纳入前列腺癌患者的标准治疗方案:时不我待

Shore, Neal; Nielsen, Sarah M; Esplin, Edward D; Antonarakis, Emmanuel S; Barata, Pedro C; Beer, Tomasz M; Beltran, Himisha; Bryce, Alan; Cookson, Michael S; Crawford, E David; Dorff, Tanya B; George, Daniel J; Heath, Elisabeth I; Helfand, Brian T; Hussain, Maha; Mckay, Rana R; Morgans, Alicia K; Morris, Michael J; Paller, Channing J; Ross, Ashley E; Sartor, Oliver; Shen, John; Sieber, Paul; Smith, Matthew R; Wise, David R; Armstrong, Andrew J